If you have been reading about Foundayo and want to understand orforglipron: how does it work, the short answer is that it copies the action of a natural gut hormone called GLP-1. Where the best-known GLP-1 medicines are weekly injections, orforglipron is designed to do a similar job as a once-daily tablet. This article explains the biology in plain English, without the hype in either direction.
This is information only, not medical advice. Orforglipron is a prescription-only medicine, and a qualified prescriber is the person who decides whether any treatment is suitable for you.
What is GLP-1, and why does it matter?
GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after you eat. It has several jobs. It tells the pancreas to release insulin when blood sugar rises, it reduces the release of glucagon (a hormone that pushes blood sugar up), it slows how quickly the stomach empties, and it acts on appetite centres in the brain to increase feelings of fullness.
The natural hormone is broken down within minutes, so it is not useful as a medicine on its own. Drug developers set out to create longer-lasting molecules that could bind to the same receptor and keep the signal going for much longer.
Orforglipron: how does it work at the receptor?
Orforglipron is what pharmacologists call a non-peptide GLP-1 receptor agonist. Let's unpack that.
An agonist is a molecule that binds to a receptor and activates it, mimicking the body's own signal. The GLP-1 receptor sits on the surface of cells in the pancreas, gut and brain. When orforglipron docks onto this receptor, the cell behaves much as it would if natural GLP-1 had arrived — nudging up insulin when needed, calming appetite and slowing digestion.
The important word is non-peptide. Injectable GLP-1 medicines such as semaglutide and tirzepatide are peptides — chains of amino acids, essentially small protein fragments. Your digestive system is very good at breaking proteins apart, which is one reason those medicines have traditionally been injected: swallowed, they would largely be destroyed before reaching the bloodstream.
Orforglipron is a small molecule built by chemical synthesis rather than a peptide. Small molecules are far more robust in the acidic, enzyme-rich environment of the gut, so a useful amount can be absorbed after swallowing a tablet.
Why the small-molecule design matters
Because orforglipron is not a peptide, it does not need the special absorption tricks that oral semaglutide requires — such as strict fasting and taking the tablet with only a sip of water. This is one reason the tablet has attracted so much attention: a genuinely convenient oral GLP-1 could widen access for people who are uncomfortable with injections. You can read more about where the medicine sits in Lilly's pipeline on our development page.
What happens in the body after you take it
Once absorbed, orforglipron circulates and activates GLP-1 receptors in several places at once:
- In the pancreas — it supports insulin release in a glucose-dependent way, meaning it mainly acts when blood sugar is raised. This lowers the risk of causing very low blood sugar on its own.
- In the stomach — it slows gastric emptying, so food stays in the stomach longer and you feel full sooner and for longer.
- In the brain — it acts on appetite-regulating centres, reducing hunger and the drive to eat.
Together these effects tend to reduce how much a person eats, which over weeks and months can lead to weight loss and, in people with type 2 diabetes, better blood-sugar control.
How does it compare with the injections?
Mechanically, orforglipron and injectable GLP-1 medicines are cousins: they all target the GLP-1 receptor. There are important differences, though.
Semaglutide (the active ingredient in some well-known weekly injections) is a single GLP-1 agonist. In the STEP 1 trial, semaglutide 2.4 mg produced average weight loss of around 15% over 68 weeks alongside lifestyle changes. Tirzepatide is a dual agonist — it activates both the GLP-1 and GIP receptors — and in SURMOUNT-1 produced average weight loss of around 21% at the top dose.
Orforglipron targets only the GLP-1 receptor, like semaglutide, but delivers it as a daily oral tablet rather than a weekly jab. How its real-world results ultimately compare will depend on the full body of trial evidence and regulatory review. We keep a general summary on our home page and track the approval picture on our UK availability page.
Because it works the same way, the side effects are familiar
Since orforglipron activates the same receptor as other GLP-1 medicines, its side-effect profile tends to follow the same pattern. The most common effects are gastrointestinal — nausea, vomiting, diarrhoea and constipation — and they are usually most noticeable when a dose is first started or increased. Slowing the stomach is exactly the mechanism that helps with appetite, so it is no surprise the gut feels it too.
Prescribers generally start low and increase the dose gradually to help the body adjust. You can read more on our side effects page and about the step-up approach on our dosage page.
A word on safety and where to get information
Orforglipron is a prescription-only medicine. That means suitability, dose and monitoring are decisions for a registered prescriber working through a GPhC-registered pharmacy or a CQC-regulated clinic. Please avoid any source selling GLP-1 products without a prescription, and be especially wary of "compounded" or unlicensed versions advertised online — these fall outside UK safety regulation and their contents cannot be assured.
If cost comes up, be aware that private prices vary between regulated providers; it is worth comparing carefully and asking what the fee includes. This site does not name sellers or quote prices.
The bottom line
Orforglipron works by mimicking GLP-1, a natural appetite- and blood-sugar-regulating hormone. Its cleverness lies in the chemistry: a durable small molecule that survives digestion, letting a GLP-1 medicine be taken as a daily tablet instead of a weekly injection. The biological effects — fuller for longer, steadier blood sugar, reduced appetite — are the same familiar GLP-1 story, delivered in a new way. For more common questions, see our FAQ page.
Frequently asked questions
Is orforglipron the same as semaglutide?
No. Both activate the GLP-1 receptor, but semaglutide is a peptide (usually injected, sometimes taken as a specially formulated tablet), whereas orforglipron is a non-peptide small molecule designed as a straightforward daily tablet.
Does orforglipron work without changing my diet?
In trials, GLP-1 medicines are studied alongside diet and activity changes. The medicine reduces appetite, which makes eating less easier, but it is intended to support lifestyle changes, not replace them.
Why can orforglipron be a tablet when other GLP-1 drugs are injected?
Because it is a small chemical molecule rather than a peptide, it resists being broken down in the gut and can be absorbed after swallowing — something peptide medicines struggle to do.
Does it cause low blood sugar?
On its own, GLP-1 receptor agonists mostly act when blood sugar is raised, so the risk of hypoglycaemia is low. The risk can increase if combined with certain other diabetes medicines — a prescriber will advise.
Is orforglipron approved in the UK?
Approval status can change. We keep a general overview on our UK availability page; the MHRA is the authority on licensing decisions.
Is this article medical advice?
No. This is general information only. Orforglipron is prescription-only, and a qualified prescriber should decide whether it is suitable for you.